# A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Source: https://onco.cc/trials/nct06842498/  
OnCo record `nct06842498` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of FG-3246 in prostate cancer, run by Kyntra Bio, now recruiting.

## Summary

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a phase 2 interventional study registered as NCT06842498 by Kyntra Bio, with 75 participants planned, started 2026-02-22 and due to reach its primary completion in 2028-03-31. Interventions recorded: FG-3246.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06842498
- Phase: 2
- Setting: A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer
- Sponsor: Kyntra Bio
- Enrolled: 75

## Sources

- ClinicalTrials.gov NCT06842498: https://clinicaltrials.gov/study/NCT06842498

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct06842498.json